Johns Hopkins University’s Brain Science Institute (BSI) has entered into a licensing agreement with Eisai, Inc., for the development of therapies to treat neurodegenerative diseases. Launched in 2009, BSI’s NeuroTranslational Program partners drug developers with researchers in effort to translate basic discoveries into therapeutics. Under the agreement, Eisai will develop small molecule inhibitors of an enzyme that may be involved in accelerating the neurodegeneration seen in diseases such as ALS and Alzheimer’s, as well as following a stroke. “It is a great accomplishment for this team to announce a licensing agreement of this kind within its first year of operation,” said Jeff Rothstein, M.D., professor of neurology and director of the program, in a Johns Hopkins release.
Click here to read more.Share this: